Q-omics provides the consensus-scored FAM238B profile across patient tissues and cancer cell-line models. FAM238B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM238B is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, FAM238B RNA expression shows 11,363 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where FAM238B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM238B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM238B survival associations across molecular data types. FAM238B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM238B RNA expression–survival associations across cancer types. High FAM238B expression shows unfavorable associations in KIRC, UCEC, MESO, STAD and CHOL, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM238B RNA expression.
This table summarizes FAM238B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM238B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM238B shows higher tumor expression in HNSC, LIHC, STAD, UCEC, KIRC and LUAD. The HNSC box plot shows higher FAM238B RNA expression in tumor versus normal tissue (log2 FC = +0.094, t-test p = .015).
This table shows molecular features associated with FAM238B in patient tissues and cancer cell lines. In patient samples, FAM238B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
